In:
Journal of Cardiovascular Pharmacology and Therapeutics, SAGE Publications, Vol. 8, No. 1 ( 2003-03), p. 25-30
Abstract:
Background: The correlation of the angiotensin-converting enzyme insertion/deletion polymorphism with essential hypertension shown in previous studies is controversial, and the responses of hypertensive patients with different angiotensin-converting enzyme genotypes to treatment with an angiotensin-converting enzyme inhibitor merits investigation. Methods: Eighty-nine patients with essential hypertension and 102 normotensive subjects were included in this study. All subjects were genotyped by polymerase chain reaction for the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Blood pressure was measured before and after taking Benazepril 10 mg, once daily, for 2 months. Results: The genotype and allele frequencies were similar (X 2 = 0.64, P = .73; x 2 = 0.36, P = .55, respectively). The reduction of both systolic and diastolic blood pressure in the DD genotype was significantly greater than in the II genotype (10.13 ± 4.91 vs 5.37 ± 2.79, P 〈 .01; 7.47 + 3.50 vs 4.71 ± 2.40, P 〈 .05, respectively). Conclusions: No significant association of angiotensin-converting enzyme gene polymorphism with essential hypertension was found. Angiotensin-converting enzyme gene polymorphism might be related to the antihypertensive response to an angiotensin-converting enzyme inhibitor in hypertensive patients.
Type of Medium:
Online Resource
ISSN:
1074-2484
,
1940-4034
DOI:
10.1177/107424840300800i105
Language:
English
Publisher:
SAGE Publications
Publication Date:
2003
detail.hit.zdb_id:
2230155-0
Bookmarklink